Compare IT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | JAZZ |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | Ireland |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.4B |
| IPO Year | 2010 | 2007 |
| Metric | IT | JAZZ |
|---|---|---|
| Price | $143.46 | $194.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $216.63 | ★ $216.92 |
| AVG Volume (30 Days) | ★ 1.3M | 734.6K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.65 | N/A |
| Revenue | ★ $2,021,441,000.00 | $1,618,693,000.00 |
| Revenue This Year | $3.64 | $6.13 |
| Revenue Next Year | $5.12 | $7.75 |
| P/E Ratio | $14.87 | ★ N/A |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $139.18 | $98.96 |
| 52 Week High | $451.73 | $200.24 |
| Indicator | IT | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.63 | 62.56 |
| Support Level | $142.32 | $159.78 |
| Resistance Level | $163.50 | $198.00 |
| Average True Range (ATR) | 7.02 | 4.92 |
| MACD | -0.54 | 0.83 |
| Stochastic Oscillator | 7.53 | 72.14 |
Gartner Inc delivers actionable, objective business and technology insights that drive smarter decisions and stronger performance on an organization's mission-critical priorities. It delivers its products and services globally through three reportable segments - Business and Technology Insights, Conferences and Consulting. Insights equips executives and their teams from every Majority function, geography, industry and sector with actionable, objective insights, guidance and tools. Conferences provides executives and teams across an organization the opportunity to learn, share and network. and Consulting serves senior executives technology-driven strategic initiatives leveraging the power of Gartner's actionable, objective insight. The Majority revenue is derived from the Insights segment.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.